2007 Fiscal Year Final Research Report Summary
Analysis of the relationship between cannabinoid system inpancreatic islets and hyperinsulinemia
| Project/Area Number |
18591000
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
NAKATA Masanori Jichi Medical University, School of Medicine, Associate Professor (10305120)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YADA Toshihiko Jichi Medical University, School of Medicine, Professor (60166527)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | cannabinoid / insulin secretion / pancreatic β-cell / metabolic syndrome |
|---|
| Research Abstract |
Obesity is the main risk factor for the development of metabolic syndrome. Endogenous cannabinoids act on the cannabinoid type 1 (CB1) receptor and stimulate appetite via central and peripheral actions, while blockade of CB1 receptor reduces body weight in humans. In this study, we aimed to explore a role of the peripheral endocannabinoid system in insulin secretion, which could be important in the metabolic effects of the cannabinoid-CB1 system. We found that mRNA for CB1 receptor, but not CB2 receptor, was expressed in mouse pancreatic islets using RT-PCR. Immunohistochemical study revealed that CB1 receptor was expressed in β-cells. Furthermore, anandamide and a CB1 agonist, arachidonylcyclopropylamide (ACPA), inhibited glucose-induced insulin secretion from mouse pancreatic islets. Both anandamide and ACPAinhibited glucose-induced cytosolic Ca^<2+>oscillation in mouse pancreatic β-cells. These results demonstrate a novel peripheral action of cannabinoids to inhibit insulin secretion via CB1 receptors.
|
